Firestone et al. noted that patients with MM who experienced CRS following treatment with a bispecific T cell engager had significantly longer PFS, where a smaller pretreatment Treg (CD25+CD127low) proportion among T cells (and an increase in CD8+ T cell proportion) was found to be one of the major drivers for improved response (15). This evidence concerns the gene IL2RA and Miyoshi myopathy.